8.87  -0.28 (-3.06%)		10-08 16:00
Open: 9.31 High: 9.31 Volume: 10,287		Pre. Close: 9.15 Low: 8.7 Market Cap: 10(M)

Short term
Mid term
Targets	6-month :	13.46	1-year :	15.51
Resists	First :	11.53	Second :	13.27
Pivot price	10.23
Supports	First :	8.69	Second :	7.23
MAs	MA(5) :	9.31	MA(20) :	10.44
	MA(100) :	12.22	MA(250) :	11.6
MACD	MACD :	-0.7	Signal :	-0.5
%K %D	K(14,3) :	9.4	D(3) :	10.4
RSI	RSI(14): 34.9
52-week	High :	18.2	Low :	2.88

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ PLRZ ] has closed above bottom band by 1.8%. Bollinger Bands are 34.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	9.33 - 9.38	9.38 - 9.44
Low:	8.56 - 8.61	8.61 - 8.68
Close:	8.76 - 8.86	8.86 - 8.97

Polyrizon Ltd. is an Israeli biotechnology firm specializing in the creation of medical device hydrogels, delivered as nasal sprays. These innovative sprays are designed to form a protective barrier within the nasal cavity, preventing viruses and allergens from attaching to the nasal epithelial tissue. Its current development pipeline features several targeted solutions, including PL-14, formulated to block nasal allergies; PL-15, aimed at combating COVID-19; and PL-16, for influenza prevention. Established in 2005, the company operates from its headquarters in Ra'anana, Israel.

Mon, 05 Oct 2026
Polymers designed to coat tissue underpin Polyrizon (PLRZ)'s new U.S. patent application. - Stock Titan

Mon, 05 Oct 2026
A material that sticks to nasal tissue could deliver medicines. Polyrizon filed a U.S. patent application. - Stock Titan

Fri, 02 Oct 2026
Polyrizon Ltd. SEC Filing (Oct 2, 2026) - Stock Titan

Mon, 28 Sep 2026
First human trial gets approval as Polyrizon (PLRZ) reports a wider six-month loss. - Stock Titan

Sat, 05 Sep 2026
Polyrizon Raises $4 Million in Registered Direct Offering and Private Placement - The Globe and Mail

Fri, 04 Sep 2026
Polyrizon Ltd. Closes $4 Million Registered Direct Offering and Concurrent Private Placement - Quiver Quantitative

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	2 (M)
Shares Float	1 (M)
Held by Insiders	0.7 (%)
Held by Institutions	9.5 (%)
Shares Short	94 (K)
Shares Short P.Month	50 (K)

EPS	-4.91
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	13.05
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-29 %
Return on Equity (ttm)	-25.4 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-2.5
Qtrly Earnings Growth	0 %
Operating Cash Flow	-5 (M)
Levered Free Cash Flow	-3 (M)

PE Ratio	-1.82
PEG Ratio	0
Price to Book value	0.67
Price to Sales	0
Price to Cash Flow	-4.65

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.